Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 93, Issue 1, Pages 105-116Publisher
WILEY
DOI: 10.1038/clpt.2012.193
Keywords
-
Categories
Funding
- NIDDK NIH HHS [P30 DK090728] Funding Source: Medline
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK090728] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Aging is the main risk factor for most chronic diseases, disabilities, and declining health. It has been proposed that senescent cells damaged cells that have lost the ability to divide drive the deterioration that underlies aging and age-related diseases. However, definitive evidence for this relationship has been lacking. The use of a progeroid mouse model (which expresses low amounts of the mitotic checkpoint protein BubR1) has been instrumental in demonstrating that p16(Ink4a)-positive senescent cells drive age-related pathologies and that selective elimination of these cells can prevent or delay age-related deterioration. These studies identify senescent cells as potential therapeutic targets in the treatment of aging and age-related diseases. Here, we describe how senescent cells develop, the experimental evidence that causally implicates senescent cells in age-related dysfunction, the chronic diseases and disorders that are characterized by the accumulation of senescent cells at sites of pathology, and the therapeutic approaches that could specifically target senescent cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available